GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients [Meeting Abstract]
dc.authorid | Kilickap, Saadettin/0000-0003-1637-7390 | |
dc.authorid | Turna, Hande/0000-0003-0558-9371 | |
dc.authorid | Paydas, Semra/0000-0003-4642-3693 | |
dc.authorid | Beypınar, İsmail/0000-0002-0853-4096; | |
dc.authorwosid | Coşkun, Hasan Şenol/C-2070-2016 | |
dc.authorwosid | Kilickap, Saadettin/AAP-3732-2021 | |
dc.authorwosid | Turna, Hande/AAA-2972-2020 | |
dc.authorwosid | Paydas, Semra/F-3132-2018 | |
dc.authorwosid | AYDIN, Kubra/ABG-5437-2022 | |
dc.authorwosid | Beypınar, İsmail/AAN-1107-2020 | |
dc.authorwosid | Ng, Terry/AEX-1224-2022 | |
dc.contributor.author | Peled, N. | |
dc.contributor.author | Gillis, R. | |
dc.contributor.author | Kilickap, S. | |
dc.contributor.author | Froesch, P. | |
dc.contributor.author | Orlov, S. | |
dc.contributor.author | Filippova, E. | |
dc.contributor.author | Demirci, U. | |
dc.date.accessioned | 2024-06-12T11:13:44Z | |
dc.date.available | 2024-06-12T11:13:44Z | |
dc.date.issued | 2021 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.identifier.endpage | S656 | en_US |
dc.identifier.issn | 1556-0864 | |
dc.identifier.issn | 1556-1380 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | S656 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/23671 | |
dc.identifier.volume | 16 | en_US |
dc.identifier.wos | WOS:000631349602018 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.relation.ispartof | Journal Of Thoracic Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | ROS1(+) | en_US |
dc.subject | ALK(+) | en_US |
dc.subject | Lorlatinib | en_US |
dc.title | GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients [Meeting Abstract] | en_US |
dc.type | Conference Object | en_US |